Press Releases

Press Releases

June 3, 2022
WOBURN, Mass. , June 03, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced Jason Rhodes , partner at Atlas Venture, has resigned from the
June 2, 2022
WOBURN, Mass. , June 02, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced that members of its management team will present in a fireside chat
March 21, 2022
Event to begin at 8:00 AM ET WOBURN, Mass. , March 21, 2022 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced that members of its executive team and
January 10, 2022
CERPASS clinical trial with RP1 in CSCC on track to complete enrollment mid-year with the primary analysis trigger six months thereafter IGNYTE anti-PD1 failed melanoma, evaluating RP1 in combination with Opdivo ®  on track to release interim data in late 2022 Phase 2 development plan for RP2/3 to
Displaying 1 - 10 of 11